Literature DB >> 15507878

CTLA-4 (CD152) gene polymorphism at position 49 in exon 1 in Graves' disease in a Polish population of the Lower Silesian region.

Irena Frydecka1, Jacek Daroszewski, Katarzyna Suwalska, Magdalena Zołedziowska, Anna Tutak, Mirosław Słowik, Stanisław Potoczek, Tadeusz Dobosz.   

Abstract

INTRODUCTION: Graves' disease ((GD)is an autoimmune disease believed to be caused by a combination of environmental and genetic factors. The gene encoding cytotoxic T lymphocyte-associated antigen-4 (CTLA-4)is one of the candidate genes for conferring susceptibility to thyroid autoimmunity. he aim of the study was to investigate the association between the exon 1 CTLA-4 gene polymorphism A(49)G and susceptibility to GD and Graves ' ophthalmopathy (GO)as well as its severity in a Polish population of the Lower Silesia region.
MATERIALS AND METHODS: We analyzed the A(49)G exon 1 CTLA-4 gene polymorphism in 99 unrelated Polish patients with GD, of whom 50 had clinically evident GO (NOSPECS class III and higher), and 154 matched healthy subjects from the Lower Silesia region. Genomic DNA was isolated from whole frozen blood using the NucleoSpin Blood kit. A/G transition was genotyped by polymerase chain reaction followed by labeling with the SnaPshot kit of PE Applied Biosystems and detected using an ABI PRISM 310 capillary genetic analyzer.
RESULTS: The distribution of CTLA-4 exon 1 A(49)G enotype, allele, and phenotypic frequencies did not differ between patients with GD and healthy subjects. There was a significantly lower frequency of the AA genotype in the group of patients with clinically evident GO than in patients without severe GO (22% vs. 43%; p=0.02, OR=2.6).
CONCLUSIONS: Our results showed that the AA genotype in patients with GD is associated with a lower risk of GO severity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15507878

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  8 in total

Review 1.  The Role of the Immune System in the Development of Endometriosis.

Authors:  Monika Abramiuk; Ewelina Grywalska; Paulina Małkowska; Olga Sierawska; Rafał Hrynkiewicz; Paulina Niedźwiedzka-Rystwej
Journal:  Cells       Date:  2022-06-25       Impact factor: 7.666

2.  Association of the CTLA4 gene CT60/rs3087243 single-nucleotide polymorphisms with Graves' disease.

Authors:  Weizhen Fang; Zhixian Zhang; Jin Zhang; Zhenhua Cai; Hua Zeng; Mei Chen; Junqi Huang
Journal:  Biomed Rep       Date:  2015-07-27

3.  Graves' ophthalmopathy: a review of immunogenetics.

Authors:  Omid Khalilzadeh; Sina Noshad; Armin Rashidi; Aliakbar Amirzargar
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

4.  Associations of CTLA4 Gene Polymorphisms with Graves' Ophthalmopathy: A Meta-Analysis.

Authors:  Pengfei Du; Xiaojie Ma; Changjiang Wang
Journal:  Int J Genomics       Date:  2014-07-09       Impact factor: 2.326

Review 5.  Thyroid-Associated Orbitopathy and Biomarkers: Where We Are and What We Can Hope for the Future.

Authors:  Natacha Turck; Simone Eperon; Maria De Los Angeles Gracia; Aurélie Obéric; Mehrad Hamédani
Journal:  Dis Markers       Date:  2018-03-15       Impact factor: 3.434

6.  Investigation of the Correlation between Graves' Ophthalmopathy and CTLA4 Gene Polymorphism.

Authors:  Ding-Ping Chen; Yen-Chang Chu; Ying-Hao Wen; Wei-Tzu Lin; Ai-Ling Hour; Wei-Ting Wang
Journal:  J Clin Med       Date:  2019-11-02       Impact factor: 4.241

7.  CLTA-4 Expression is Associated with the Maintenance of Chronic Inflammation in Endometriosis and Infertility.

Authors:  Monika Abramiuk; Dominika Bębnowska; Rafał Hrynkiewicz; Paulina Niedźwiedzka-Rystwej Grzegorz Polak; Jan Kotarski; Jacek Roliński; Ewelina Grywalska
Journal:  Cells       Date:  2021-02-25       Impact factor: 6.600

8.  Association between the CTLA-4 +49A/G polymorphism and Graves' disease: A meta-analysis.

Authors:  Xiaoyu Si; Xiufeng Zhang; Wenru Tang; Ying Luo
Journal:  Exp Ther Med       Date:  2012-06-20       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.